Seizure disorder is the third most common neurological disorder in the elderly after stroke and dementia. With the increasing geriatric population, the situation of clinicians seeing more and more elderly epilepsy patients is very likely. Not only is the diagnosis of epilepsy tedious in the elderly, its management raises many challenging issues for the treating physicians. Altered physiology, age-related decline in organ function, and plasma protein binding and altered pharmacodynamics make the elderly patients with seizure disorder a difficult group to treat. This is further complicated by the presence of comorbidities and polypharmacy which increase the chances of drug interactions. The adverse effects that might be tolerated well in younger populations may be disastrous for the aged. Although the newer antiepileptic drugs are found to have a favorable safety profile, there is relative scarcity of randomized-controlled trials involving older and newer antiepileptics in the geriatric population. This review tries to compile the available literature on management of epilepsy in the elderly population including evidence of safety and efficacy of newer and older antiepileptics with special reference to the 'geriatric giants'. It also deals with the interactions between antiepileptic medications and other commonly prescribed drugs in the elderly such as anti-hypertensives and antiischemic agents. The recommended guidelines of various international bodies are also analyzed from the perspective of elderly with seizure disorder.
Introduction
Seizure disorder is the third commonest neurological disorder in elderly after stroke and neurodegenerative diseases [1] . Its incidence and prevalence is maximum in those above 65 years. Etiology and presentation of seizures in elderly differ from that in adults. Mostly, stroke, neurodegenerative disorders, infections, and metabolic insults lead to seizures in elderly. These patients often suffer from other illnesses like cerebrovascular disease, diabetes, hypertension, cardiac arrhythmias, malignancies, chronic bronchitis, osteoporosis, osteoarthritis, Alzheimer's disease, and Parkinsonism. Immobility, instability, altered vision and hearing, incontinence, and impaired cognition are the 'giants' afflicting the elderly. The presence of these comorbidities along with issues like altered physiology and pharmacology, atypical disease presentations, caregiver dependence, polypharmacy, and self-medication are the reasons which make this population unique. Older people often receive antihypertensives, cholesterol-lowering drugs, antidiabetics, antianginals, antiplatelets, anticoagulants, cognition enhancers, analgesics, and antiinflammatory and anti-Parkinsonian medications. Simultaneous use of these with antiepileptic drugs (AEDs) may result in suboptimal or supratherapeutic concentrations of antiepileptics, raising the importance of therapeutic drug monitoring. Another confusing area is the choice of antiepileptic in elderly. Traditionally used AEDs like phenytoin, valproate, and carbamazepine are often preferred owing to enormous evidence of efficacy in adults, low cost, and easy availability. These, however, carry a higher risk of adverse effects. Newer antiepileptics like lamotrigine, levetiracetam, oxcarbazepine, and gabapentin have been launched, which are believed to be non-inferior to older antiepileptics and carry a lesser risk of drug interactions and adverse effects. In this review, the authors briefly introduce how epilepsy in the elderly differs from that in the young with special emphasis on therapeutic aspects. They also try to compile the relevant literature on the pattern of prescribing antiepileptics in the elderly, safety, and efficacy of older and newer antiepileptics in this population, the available international guidelines on management of seizure disorder in the elderly, and the effect of antiepileptic drugs on major health-related geriatric domains.
Epilepsy in elderly
Focal-onset seizures are more common in the elderly as compared to the young adult population. Whereas generalized convulsions and automatisms are less often seen in the elderly, atypical presentations as dizziness and confused behavior as also progression to status are all more common in this group. Similarly, the chance of recurrence of seizure is more in the elderly with respect to the young, except for that seen in congenital epilepsy syndromes. A particularly dramatic difference is in the period of post-ictal confusion which may last up to 2 days in the elderly as opposed to minutes to a few hours in the young [1, 2] .
Pattern of prescribing antiepileptics in elderly
Despite many recommendations favoring the use of newer antiepileptics, the shift from older antiepileptics has been relatively recent and variations exist in prescription patterns. A study on geriatric patients with newly diagnosed epilepsy (2000) (2001) (2002) (2003) (2004) from the Veterans Health Administration database showed that, despite increasing use of newer antiepileptics in older patients, phenytoin is still most preferred [3] . Similarly, a retrospective study conducted in Brazil to find the prescribing pattern in hospitalized elderly patients (n = 109) found phenytoin and carbamazepine to be most commonly prescribed and lamotrigine the least. Phenytoin preference was attributed to its availability as intravenous preparation, ease of switching to oral formulation, low cost, and enormous evidence of efficacy. In contrast, lamotrigine, owing to the risk of rash, requires slow titration over weeks to achieve a maintenance dose. This and the lack of parenteral formulations might be the reason for reluctance among physicians to use lamotrigine, especially when rapid seizure-control is desired [4] . Another recently conducted Finnish study observed valproate and carbamazepine as preferred initial antiepileptics in elderly [5] . The same two antiepileptics were found to be commonly used in patients with post-stroke seizures in a nationwide survey conducted in Japan [6] . However, data from several other studies, albeit from developed countries, highlight a growing preference for newer antiepileptics such as gabapentin, levetiracetam, and lamotrigine (Supplementary Table 1 ) [7] [8] [9] .
Safety and efficacy of newer antiepileptics
A recently conducted meta-analysis comparing the efficacy and tolerability of newer antiepileptics in adult patients with refractory epilepsy found topiramate to have maximum efficacy reflected by a 50% reduction in seizure frequency, followed by levetiracetam. Lamotrigine was found to be the least efficacious. Pregabalin had the maximum somnolence potential. Of the 32 trials included, only one had enrolled elderly patients, thus reducing its generalizability [10] . A post hoc analysis of a superiority study tested continuation rates of various AEDs among elderly. Time to treatment withdrawal was longest with levetiracetam (LEV) [11] . A retrospective study from New York compared the effectiveness of ten antiepileptics in 417 elderly out-patients. The antiepileptics studied were lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, phenytoin, topiramate, zonisamide, valproate, gabapentin, and clobazam. There were differences in retention rates which were unrelated to efficacy but due to differences in adverse effects. Lamotrigine and levetiracetam fared the best in clinical efficacy and retention rates and oxcarbazepine the poorest. The commonest adverse effect, also reason for discontinuation, was imbalance in case of lamotrigine, drowsiness, and psychiatric manifestations with levetiracetam, allergies in case of phenytoin, drowsiness for carbamazepine, and tremors in case of valproate [12] . Supplementary Table 2 details recent studies on the safety and efficacy of antiepileptics in elderly patients [10] [11] [12] [13] [14] [15] .
Pharmacokinetic features of antiepileptics
Decline in liver and renal function, reduction in plasma protein levels and total body water, and increase in body fat are some of the important age-related pharmacokinetic changes which can influence the plasma AED concentrations. Phenytoin is metabolized by CYP2C9-and CYP2C19-mediated oxidation and excreted in urine. It has high plasma protein binding and is a strong inducer of CYP3A4. Thus, it is involved in a multitude of drug interactions. Carbamazepine is metabolized by CYP3A4 and its active epoxide moiety then undergoes glucuronidation followed by urinary excretion. Like phenytoin, it also increases the metabolism of other drugs metabolized by CYP3A4. Valproate is rather an enzyme inhibitor and increases the concentration of concomitant drugs. Valproate itself is subjected to metabolism by CYP2C9 and UGT, and is also highly bound to plasma proteins. Among newer antiepileptics, lamotrigine undergoes glucuronide conjugation and is excreted in urine [16] . Gabapentin and pregabalin are excreted unchanged in urine [17] . A greater fraction of topiramate is excreted unchanged in urine and 30-50% is subjected to oxidation in the liver [18] . Similarly, levetiracetam is largely removed by the renal route and only around 30% is subjected to esterase [19] . The new generation antiepileptics have low plasma protein binding and are not potent enzyme inducers. This reduces the risk of clinically significant drug interactions. OXC is rapidly converted into active metabolite monohydroxy derivative (MHD). It is not a strong enzyme inducer/inhibitor, but, at a dose > 1200 mg/day, it can decrease the metabolism of phenytoin by 40% [20] . OXC can also produce modest decline in levels of LTG and TPM [21] . Tables 1, 2 show the common plausible interactions of antiepileptics with drugs used in the elderly for varied indications [18, 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] .
Guidelines on management of epilepsy in the elderly
Other than some recommendations for focal seizures, there have been no guidelines till date that emphasize on drugs suitable to be given as the first-line antiepileptics in elderly patients (Table 3 ) [33] [34] [35] . For newly diagnosed and untreated focal seizures, lamotrigine and gabapentin have been considered as efficacious monotherapy with high level of evidence [33] [34] [35] . As opposed to the 'wait-and-watch' policy sometimes followed in initiating treatment for a first unprovoked seizure in the young, AEDs should be initiated for any seizure in the elderly. This is because of a higher risk of recurrence and high mortality thereafter. Furthermore, other factors such as presence of neurologic deficit, risk/ benefit ratio, cognitive status, and wish of the patient need consideration [1, 2] . Supplementary Table 3 gives the dosing recommendations for AEDs in elderly patients.
Antiepileptics and geriatric comorbiditieseffects and interactions

Antiepileptics and effects on cognition
Older antiepileptics including phenytoin, carbamazepine, valproate, and phenobarbitone have been linked to cognitive impairment in various age groups. Among these, phenobarbitone is especially notorious. Phenytoin has been linked to disturbances in attention, visuomotor function, and mental speed, though overall effect is small [36] . The cognitive profile of carbamazepine and valproate is similar and slightly better than phenytoin [36] . Among newer antiepileptics, topiramate has been shown to negatively affect cognitive domains in nearly 10% patients [37] . This may be lessened by slow titration and monotherapy. While oxcarbazepine, pregabalin, and gabapentin have been linked to mild cognitive effects, lamotrigine and levetiracetam are thought to be virtually free of these. Rather, unexplained positive effects have been seen in some studies [38] . Polytherapy has been observed to worsen cognition more. A retrospective analysis of ten antiepileptic drugs, both older and newer ones prescribed to elderly, showed that cognitive adverse effects are common in patients on topiramate followed by those on zonisamide and gabapentin [12] . Assessment of the effect of antiepileptic drugs on cognition has been a difficult task. Epilepsy itself is known to damage brain areas linked with complex task performing activities. Type of seizures, location of epileptogenic focus, dose and duration of antiepileptic drug use, age of patient at drug initiation and at time of onset of cognitive dysfunction, and use of concomitant drugs are the issues which remain inadequately addressed in the studies done so far [36] .
Antiepileptics and cardiovascular disease/metabolic syndrome
Antiepileptic drugs which block neuronal sodium channels can contribute to cardiac rhythm defects by interfering with phase 0 of action potential. Phenytoin used as monotherapy or combined with other Na +-channel blockers like carbamazepine and lamotrigine has been linked to ECG findings similar to Brugada syndrome [39] . Intravenous phenytoin at high infusion rate has been linked with hypotension and arrhythmias. As compared to young adults, a lower infusion rate of 25-30 mg/min is recommended for the elderly and up to 10-20 mg/min in those with cardiovascular disease [40] . Phenytoin is contraindicated in patients with heart rate less than 60/min or with second/third degree heart block [40] . Lamotrigine and carbamazepine have been associated with slight increase in PQ interval and decline in heart rate in elderly, however, without significant ECG differences [41] . Carbamazepine and oxcarbazepine should also be avoided in settings of atrioventricular block [42] . They may also aggravate hyponatremia associated with diuretic use and can potentiate dilutional hyponatremia in congestive heart failure. Though there have been reports of aggravation of heart failure by pregabalin and occurrence of SUDEP with lamotrigine, the evidence at present is limited. There have been a few studies assessing the impact of antiepileptic drugs on cardiovascular risk factors in the elderly. Carbamazepinetreated young patients have been shown to have elevations in total cholesterol, LDL, and HDL values [43] . Similarly, phenytoin can elevate LDL, HDL, and cholesterol levels, 1 3 [44] . In another study, significant decline in total cholesterol, triglyceride, and non-HDL cholesterol was seen after patients on phenytoin or carbamazepine were shifted to levetiracetam or lamotrigine [45] . Eslicarbazepine has been found to not produce unfavorable effects on lipid metabolism in a recent retrospective study [46] . Long-term use of phenytoin, valproate, and carbamazepine has been linked with increased common carotid intima media thickness, an independent risk factor for cerebrovascular and cardiovascular disease. Valproate has been associated with metabolic syndrome and insulin resistance. Nonalcoholic fatty liver disease (NAFLD) has been observed with valproate and carbamazepine use. Valproate, carbamazepine, pregabalin, and gabapentin are linked with weight gain. Lamotrigine, oxcarbazepine, and levetiracetam are weight neutral, while topiramate and zonisamide are known to cause weight reduction [47] .
Antiepileptics and bone health
Epilepsy can lead to falls and fractures, particularly in elderly. This is compounded by the tendency of AEDs to decrease bone strength and bone mineral density. Cerebellar disturbances produced by AEDs may result in falls and trivial trauma may produce fractures. Phenytoin and carbamazepine, by acting as enzyme inducers, can decrease the [48] . Among newer antiepileptics, gabapentin was found to increase bone loss in community-dwelling older men. How gabapentin causes bone loss is unclear, but activation of central sympathetic nervous system and inhibitory action of norepinephrine on osteoblasts has been hypothesized. Increased risk of fractures was found with gabapentin and clonazepam in another retrospective study on older epilepsy patients. Interestingly, the study found valproate to be safe [49] . The data considering levetiracetam and topiramate are conflicting. Considering the impact of antiepileptics, particularly the older ones on bone homeostasis, serum vitamin D, calcium, phosphate, and alkaline phosphatase should be measured at least annually in patients taking antiepileptics and daily oral supplements with 1-1.5 g calcium and 1000-2000 IU of Vitamin D3 should be ensured. Dose of vitamin D3 can be increased up to 4000 IU/day if phenytoin or carbamazepine is being used [50] . There are no universal guidelines on prophylactic use of bisphosphonates, calcitonin, or hormonal replacement therapy for the prevention of osteoporotic fractures in elderly on AEDs. These can be tried, however, considering the risk of fractures.
Antiepileptics and urinary problems
There have been several reports of carbamazepine-induced urinary retention both in males and females. Carbamazepine structurally resembles TCAs and can produce anticholinergic symptoms within days to months. Carbamazepine and, to a variable extent, oxcarbazepine have ADH like action which contributes to water retention [51] . They should, therefore, be avoided in elderly patients suffering from prostatic or other causes of urinary tract obstruction. Because of the anticholinergic profile of carbamazepine, it should be avoided in elderly patients with glaucoma and chronic constipation. Prophylactic lubricant eye drops and stool softeners can be advised in susceptible populations. Gabapentin has been shown to be associated with urinary and fecal incontinence in elderly patients. Incontinence was seen to occur within 1-4 weeks of therapy initiation and was found to be reversible with drug discontinuation [52] . Probable mechanisms suggested include modulation of GABAergic neuronal supply to the external urethral sphincter, causing its relaxation; and modulation of α2δ subunit of N-type Ca 2+ channels present on A-δ and C-fibers, resulting in decreased calcium entry and poor detrusor contraction. As a corollary, the resulting increase in bladder capacity might be useful in neurogenic overactive bladder. The central action of gabapentin on the micturition center in pons via modulation of GABA and glutamate is another tentative mechanism. Topiramate can cause nephrolithiasis and metabolic acidosis by inhibition of carbonic anhydrase in the kidney. This may predispose the vulnerable elderly to urinary retention and infections. Lamotrigine-induced burning sensation over vulvar area and painful micturition has been described in an adult female with bipolar depression [53] . Reversible day time enuresis has been shown to be associated with valproate (at 900 mg/day) [54] . Till date, there have been no 
Antiepileptics and hyponatremia
Hyponatremia is the commonest electrolyte abnormality seen in elderly and an independent risk factor for mortality. Stroke which is the commonest cause of seizures in elderly is known to cause hyponatremia. This emphasizes the need to use the antiepileptic with least potential to cause hyponatremia in elderly. Oxcarbazepine and carbamazepine have been particularly associated with a risk of hyponatremia [55] . In a recently published cohort study, risk of hyponatremia with OXC was more in those who had already experienced hyponatremia with CBZ [56] . Eslicarbazepine too is not safe in this regard. Levetiracetam use in elderly has also been linked with SIADH in a few case reports [57] . Risk exists with phenytoin, valproate, and topiramate, as well [55] . The explanation for association of phenytoin and hyponatremia is obscure, since the drug is known to induce a diabetes insipidus like state.
Antiepileptics and psychiatric disorders
Depression is encountered as a common comorbidity in patients suffering from epilepsy. The inevitable concomitant use of antiepileptics and antidepressants in epilepsy patients with depression is accompanied by many pharmacokinetic and pharmacodynamic drug interactions (Table 1) . Valproate, carbamazepine, oxcarbazepine, and lamotrigine are used as mood stabilizers in bipolar disorder (BPD). They are also useful in the management of depression as an adjunct to standard antidepressants. On the other hand, levetiracetam has been shown to cause depressive features like anhedonia, change in sleep patterns, and fatigability in elderly patients [58] . In the adverse event analysis part of a comparative study done in the elderly population, neuropsychiatric adverse effects were commonly seen with levetiracetam and clobazam followed by topiramate, gabapentin, and oxcarbazepine [12] . In contrast, there are studies in adult epilepsy patients where levetiracetam has been linked with improvement in depression and anxiety scores [59] . In light of limited studies assessing the neuropsychological effects of antiepileptics in elderly and variable findings in adults, it might not be wrong to suggest that use of any antiepileptic in general should be stopped or withheld if there is clinically significant worsening of mental status after its initiation. Compared to the general population, suicide risk is five times higher in epilepsy patients and this is influenced by the nature of AED being used. In a retrospective database study, suicide-related behavior was found to be strongly associated with the use of antiepileptic drugs (gabapentin, lamotrigine, topiramate, levetiracetam, phenytoin, and valproate) in elderly patients (hazard ratio = 4.5) [60] . This is contrary to the findings of a well-cited study where lamotrigine and valproate were almost given antisuicidal status [61] . Many of these observational studies have been criticized owing to inconsistencies in the methods and presence of confounding factors. The mortality risk of not prescribing antiepileptics is high and decisions should always be individualized. Lamotrigine and valproate have been quoted to be safe in patients with concomitant psychosis, but the use of antiepileptics primarily for psychosis management should be avoided owing to limited compelling evidence [27] .
Among antiepileptics, only carbamazepine has been found to be useful in the management of behavioral and psychological symptoms of dementia (BPSD) in various controlled studies. At the same time, the drug does not have the most desirable safety profile [62] . A randomized, placebo-controlled trial, failed to show any positive effect of oxcarbazepine on BPSD with 8 week oxcarbazepine treatment [63] . Valproate, lamotrigine, and gabapentin have been shown to produce favorable results on BPSD but not in controlled studies [62] .
Antiepileptic drugs and stroke
Cerebrovascular accident is the most common cause of seizures in late age. Compared to ischemic CVA, hemorrhagic CVA is complicated by seizures more often. Post-stroke seizures can be early (< 2 weeks) or late (after 2 weeks). While late-onset seizures often require treatment, antiepileptic drugs can also be given in early post-stroke seizures in case of recurrence. Plausibility of drug interactions with older antiepileptics needs special attention (Table 1) [64] . That phenytoin, valproate, and carbamazepine can delay functional recovery after stroke has also been pointed out by some studies [65] . Newer antiepileptics like levetiracetam, lamotrigine, topiramate, and gabapentin can be preferred in such situations.
Antiepileptics and vision changes
Elderly individuals often suffer from age-related ocular pathologies like cataract, glaucoma, presbyopia, and dry eyes [66] . Carbamazepine can cause diplopia, nystagmus, change in color perception, and contrast sensitivity. These effects can come at therapeutic or toxic drug levels [67] . Because of its antimuscarinic action, it can cause dry eyes and precipitate an attack of angle closure glaucoma [68] . Topiramate use has also been linked with precipitation of attacks of angle closure glaucoma in susceptible users [66] . Phenytoin toxicity can manifest as diplopia, nystagmus, and alteration in color perception. Impaired
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color vision has also been observed with valproate. Both these drugs have been implicated in cataract formation [69] . Blurring of vision and diplopia have been observed with lamotrigine, respectively, at therapeutic and toxic dose [66] . However, there is no evidence of serious or troublesome visual insults with lamotrigine, gabapentin, levetiracetam, and oxcarbazepine.
Antiepileptic drugs and lung disease
Phenytoin and phenobarbitone can cause respiratory suppression particularly on fast intravenous administration [27] . Arterial blood gas analysis with frequent monitoring of PO 2 , PCO 2 , SO 2 , serum bicarbonate, and arterial pH should be done if such drugs are to be used in patients with asthma, COPD, pulmonary edema, or left-ventricular failure. Though rare, but gabapentin has been associated very recently with severe respiratory depression. The risk is particularly high in people with concomitant respiratory insufficiency, neurologic disease, renal dysfunction, elderly, and when used in conjunction with other CNS depressants. Despite these reports, gabapentin along with levetiracetam, lamotrigine, and valproate remains safer options in seizure disorder patients with concomitant lung disorders [27] .
Status of other new AEDs (perampanel, lacosamide, and brivaracetam)
There are no head-to-head comparison trials of perampanel, brivaracetam, and lacosamide in elderly population. Few retrospective observational studies have evaluated the efficacy and safety of lacosamide use in the elderly, the largest being of 128 patients (≥ 65 years) which observed that 68% patients with focal seizures were seizure-free at 12 months when the drug was used as monotherapy. Compared to the general population, lethargy, dizziness, and somnolence were more common in the elderly subset but without any differences in drug retention rates [70] . Perampanel use as adjunct AED has been evaluated recently in a pooled analysis of European population. 135 patients of age ≥ 65 years, mostly with focal seizures, were included in the total data set of 2396 patients. Only 28% elderly were seizure-free at 12 months [71] . In a subgroup analysis of three phase III studies assessing the efficacy of add-on perampanel therapy versus placebo, the drug was projected to have similar efficacy in elderly as that in adult patients. Adverse effects were more in the elderly, but, since the sample size of elderly patients was very small (28 patients), the results cannot be generalized [72] . As far as clinical data on brivaracetam are concerned, the authors could find only one study pertaining to elderly patients which was a pooled analysis of three phase III studies involving only 32 patients of age ≥ 65 years. Brivaracetam was used as an adjunct in focal seizures. Overall, safety and efficacy of drug were shown to be similar in elderly and adult patients. Headache, paresthesias, and somnolence were the common adverse effects [73] . Since data concerning these new AEDs are scarce in elderly, larger studies with a focus on geriatric specific complaints are needed to draw major conclusions.
Conclusion
In this review, we have tried to analyze the pharmacological issues with antiepileptic drug therapy in the elderly, the impact these drugs can have on the major health problems of elderly and the available literature on the safety and efficacy of AEDs in elderly. Clearly, the data on antiepileptic drugs in the elderly are scarce. With enough clinical experience of use of older antiepileptics in the general population, phenytoin, carbamazepine, and valproate are still the choice drugs in elderly, though the trend is shifting towards levetiracetam, gabapentin, and lamotrigine. These newer AEDs have been shown to provide equivalent seizure protection with relatively fewer interactions and adverse effects. Specific AEDs may be preferable while considering their effects on cognition, cardiac function, body weight, fracture risk, hyponatremia, urinary symptoms, ocular diseases, and the risk of respiratory depression ( Table 4 ). The authors have provided information on therapeutically relevant drug interactions involving antiepileptics and other drugs. 'Start low and go slow' technique should be followed for the management of epilepsy in the elderly. Large simple trials with head-to-head comparison of older and newer antiepileptics in elderly patients can generate evidence base and provide new insights in the field of management of epilepsy in the elderly.
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